Abstract

Various society guidelines recommend biologicals (Anti IgE Omalizumab or anti IL5 – Mepolizumab) as an add on therapy for management of severe asthma, but there is no consensus on stoppage of these drugs after obtaining good asthma control. COVID 19 pandemic with lockdowns led to unintentional & unavoidable interruption in administering these drugs and paved way for us to analyze the effects of stoppage of these biologicals in severe asthmatics well controlled on these drugs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.